

Innovative Biologics, Inc.

Contact: Jeff Conroy, CEO

Location: Herndon, Virginia

Email: jxc@innovbio.com

Tel: 703.346.0751



U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health



National Institutes of Health Commercialization Assistance Program
(NIH-CAP)

Company Profile

Industry Sector: Medical Devices


Company Overview: IBI is developing a drug which blocks pore-forming toxins, specifically α -toxin, a key virulence factor of MRSA.

- Secured \$1.8 million NIH grant funding
- \$200,000 from CIT BioLife Fund and Johnson & Johnson
- USAMRIID Anthrax collaboration
- Method and pharmaceutical composition patents


Target Market(s): Methicillin-resistant Staphylococcus aureus Infection (MRSA).

- 20,000 deaths in the US from MRSA in 2008
- Will become the third leading cause of death in the US within 5 years.
- 85% of MRSA Infections are acquired in the hospital.
- Everyone is at risk.

How We Combat MRSA



Development Timeline



Investment Summary

Investment Summary:

- \$2 million – 2 candidates – patents – leading edge science
- Know what we have to do to achieve objectives
- Executing faster and cheaper
- Seeking Series A financing of \$5 to \$7 million
- Exit transaction with pharma partner in 24 to 36 months

